Mesna

Mesna

File:Mesna.svg
Clinical data
Pregnancy category	B1 (Au), B (U.S.)
Routes of administration	Oral, intravenous
ATC code	R05CB05 (WHO) V03AF01 (WHO)
Legal status
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability	45–79% (Oral)
Metabolism	Oxidised in circulation
Elimination half-life	0.36–8.3 hours
Excretion	Renal
Identifiers
IUPAC name sodium 2-sulfanylethanesulfonate
CAS Number	19767-45-4
PubChem CID	29769
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C2H5NaO3S2
Molar mass	164.181 g/mol

Mesna (INN) (Template:PronEng) is an adjuvant used in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is currently marketed by Baxter as Uromitexan® and Mesnex®.

Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein. Mesna assists to neutralise these metabolites by binding through its sulfhydryl-moieties, and also increases urinary excretion of cysteine.

External links

• BC Cancer Agency
• NIH/Medline